Updated:
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is based in Novato; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
General information
Location
Region
North America
Country
United States
City
Novato
Corporate office
60 Leveroni Court, Novato, CA 94949, United States
Additional offices
Somerville, MA, United States · Bedford, MA, United States · Woburn, MA, United States · South San Francisco, CA, United States · Basel, Switzerland · Paris, France · Berlin, Germany · Milan, Italy · Schiphol, Netherlands · Madrid, Spain · Zurich, Switzerland · Miami, FL, United States · Olivos, Argentina · São Paulo, Brazil · Bogotá, Colombia · Mexico City, Mexico · Tokyo, Japan
Principals
Emil D. Kakkis
Chief Executive Officer and President
Sector focus
Frequently asked questions
Who runs investment decisions at Ultragenyx?
Ultragenyx is a commercial-stage biopharmaceutical company, not an investment firm. Corporate strategy and capital allocation decisions are led by CEO and President Emil D. Kakkis, M.D., Ph.D., who founded the company. As a publicly traded enterprise, material investment and pipeline decisions are disclosed through SEC filings and Nasdaq announcements.
What investment stages does Ultragenyx typically target?
Ultragenyx is not an allocator deploying into funds or external startups. It invests directly into its own clinical pipeline, moving programs from research through clinical development, regulatory approval, and commercial launch. The firm's pipeline covers assets at various stages, from preclinical gene therapy research to marketed products supported by its UltraCare access program.
Which sectors does Ultragenyx explicitly avoid?
Ultragenyx focuses exclusively on rare and ultra-rare genetic diseases. Its public disclosures do not indicate activity in common disease indications, oncology, vaccines, or medical devices. The firm's patient support infrastructure, UltraCare, is built specifically for rare disease communities with conditions that often lack any approved treatment.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: